HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Clinical trials for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS explained in plain language.
Never miss a new study
Get alerted when new HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS trials appear
Sign up with your email to follow new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough trial offers hope for patients stuck on kidney transplant waitlists
Disease control OngoingThis study is testing whether two existing drugs, daratumumab and belatacept, can help kidney transplant patients who are 'highly sensitized'—meaning their immune systems attack most donor kidneys. The treatment aims to lower these harmful antibodies, making it easier to find a c…
Matched conditions: HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for stuck on the transplant waitlist
Disease control OngoingThis study is testing whether two drugs, carfilzomib and belatacept, can help people who have been waiting a very long time for a kidney transplant. These patients have immune systems that attack most donor kidneys, making it extremely hard to find a match. The goal is to see if …
Matched conditions: HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC